Project summary
Established in 2011, ADDRESS-2 is a database of information from of people newly diagnosed with type 1 diabetes who have agreed to be involved in research. This new funding will continue to support the program and allow the team recruit more people. The team will work with the type 1 diabetes Immunotherapy Consortium to increase the number of people recruited into immunotherapy trials. These trials aim to find new ways to prevent, or cure, type 1 diabetes.
Background to research
The After Diabetes Diagnosis Research Support System (ADDRESS-2) is a database of information and biological samples from people newly diagnosed with type 1 diabetes (and their siblings) who have agreed to be contacted about research. Established in 2011, ADDRESS-2 has recruited around 60-70 people every month and is now the largest database of type 1 diabetes adults in the world, as well as one of the largest databases of children with type 1 diabetes. As studies often need to be carried out in large groups of people to make sure the findings are accurate, ADDRESS-2 is a vital resource for researchers.
Research aims
Professor Johnston and his team will continue to run ADDRESS-2 and expand the scope of the program, allowing them to reach more people newly diagnosed with type 1 diabetes who would like to take part in research.
As with the existing system, new ADDRESS-2 participants will be identified through NHS trusts, and their data will be stored in a secure database. This data can then be used to recruit people into new trials of immunotherapies. Biological samples will also be collected from people, allowing researchers to investigate the genetics related to type 1 diabetes.
The team will work closely with the type 1 diabetes Immunotherapy Consortium to make it easier for people newly diagnosed with type 1 diabetes to take part in studies looking at the early stages of the condition. ADDRESS-2 will also recruit people to take part studies later in life, following on from their diagnosis, and siblings of people with newly diagnosed type 1 diabetes for trials aiming to prevent type 1 diabetes before it develops.
Potential benefit to people with diabetes
This funding will continue to support ADDRESS-2, to help researchers recruit more people newly diagnosed with type 1 diabetes into important research trials. These trials could pioneer new treatments to dramatically reduce the impact of type 1 diabetes in those who already have it, and hopefully prevent the condition in those at high risk.
